Kangfang bio-targeted IL-4R new drug approved clinically in the United States

Currently, AK120 has completed clinical studies in New Zealand on the safety, toerability and pharmacodynamic increment of single subsurfic injection dose for healthy subjects, and is conducting clinical studies in New Zealand and Australia on multiple subsurfic injection dose increments of subsurfic injections in New Zealand and Australia.
preliminary blindness study data show that AK120 injections given to moderate to severe endexual dermatitis subjects for 1-2 weeks can quickly take effect, reduce the area of skin loss, relieve skin loss erythema, hard knots, skin peeling and other symptoms.
dermatitis is the most common disease in dermatology, with public data showing that the global incidence rate is as high as 10% and 20%, respectively, for adults and children.
, low penetration and excellent clinical performance of IL-4R monoantials are expected to meet the unfinished needs of patients worldwide, according to the press release.
press release also showed that tens of millions of patients worldwide lack more effective biologic therapies for asthma, chronic obstructive pulmonary disease and other type 2 inflammatory diseases.
the benefits of IL-4R monoantials in terms of efficacy and safety, it is expected to provide new benefits to patients with related diseases.
: The new drug AK120 has been approved in the U.S. clinical trial. Retrieved Nov 30, 2020, from Source: Medical Mission Hills